News & Trending Insurance News

Will Medicare Cover Ozempic or Wegovy in 2026? What Retirees Need to Know About GLP-1 Coverage

Changes could be coming to GLP-1 coverage for weight loss.

By Kristin Hitchcock , Edited by Laura Hohenstein

Updated May 1, 2026

Add Us On Google

There's a quiet frustration building among retirees right now, and it ties directly into how overlooked senior benefits often work in practice. You've probably seen the headlines about drugs like Ozempic and Wegovy helping people lose significant weight and improve their health.

But if you're on Medicare, the reality has been pretty simple: unless you have a qualifying condition, you're likely paying out of pocket or not getting access at all.

That may start to change in 2026. Medicare isn't fully opening the door, but it is cracking it. A temporary program could give some retirees a path to coverage, at least for a limited time. Here's how it actually works.

Now Available: The Definitive Guide to Retirement Income

Many successful investors eventually reach the same moment. The saving is done, the portfolio is built, and the question quietly changes from how much can I grow this to how much can I take out? Get that second question wrong and decades of good investing can come apart in a handful of years.

That is exactly what The Definitive Guide to Retirement Income helps answer.¹ <p class="">Investing in securities involves a risk of loss. Past performance is never a guarantee of future returns. Investing in foreign stock markets involves additional risks, such as the risk of currency fluctuations. Guides are provided by Fisher Investments. The publisher may be compensated when readers request a guide.</p> It covers what your retirement could actually cost, which income sources are worth using, and the withdrawal math that decides whether the money lasts. It is free today from Fisher Investments. Read More Here ›

Why Medicare has not covered GLP-1 drugs for weight loss

This isn't a simple policy choice. Medicare has been restricted by law from covering medications strictly for weight loss. That's why even as these drugs become more common, coverage didn't follow.

Right now, GLP-1 drugs are typically only covered when they're tied to specific medical conditions, like:

Ozempic and Mounjaro for Type 2 diabetes
Wegovy for certain patients with cardiovascular risk
Zepbound for obstructive sleep apnea

If your goal is weight loss alone, Medicare has usually said no. That's been the sticking point.

Shopping for cheaper auto insurance? Enter your zip code here to get started.

What's changing in July 2026: the Medicare GLP-1 Bridge

This is where things get interesting. Starting in July 2026, the Centers for Medicare & Medicaid Services is expected to roll out a temporary program called the "Medicare GLP-1 Bridge."

Think of it as a trial run. Under this program, some retirees may be able to get coverage for drugs like Weygovy and Zepbound even when weight loss is the main goal.

So far, we know that you'll need Part D or a Medicare Advantage plan with drug coverage. Copays could land around $50 per month for those who qualify, and your doctor will need to submit prior authorization.

It's not automatic, and it's not guaranteed. But it's a real shift from where things stand today.

Who might actually qualify

This won't be a free-for-all, though. Many people may be surprised when they don't actually qualify for coverage.

Eligibility depends on several factors, and the specifics might change between now and July. In many cases, you'll need some sort of documentation of obesity and related health issues, as well as a provider who is willing to go through the approval process. Not all plans may participate in this trial period, either.

Two retirees could have two very different approval experiences. One may get approved right away, and the other might run into roadblocks. Right now, we don't really know what that will look like in practice.

Released: The Definitive Guide to Retirement Income (Sponsor)

Most people spend their entire working lives focusing on one thing: growing a pile of money. Then they retire and discover the skill they actually need is close to the opposite. Turning that pile into steady income, year after year, through good markets and bad, without ever running out. It may be the least discussed and most consequential transition in personal finance, and plenty of otherwise careful investors walk into it with no real plan.

That is exactly what The Definitive Guide to Retirement Income helps answer.¹ <p class="">Investing in securities involves a risk of loss. Past performance is never a guarantee of future returns. Investing in foreign stock markets involves additional risks, such as the risk of currency fluctuations. Guides are provided by Fisher Investments. The publisher may be compensated when readers request a guide.</p> It is a free guide from Fisher Investments covering what your retirement will really cost, where the cash flow should come from, and how much you can safely withdraw each year. Learn More Here ›

Why this program only lasts through 2027

The GLP-1 Bridge is scheduled to end at the close of 2027. The goal isn't just to expand access. Medicare is just trying to answer some big questions, like how much the drug will cost at scale and whether they actually improve long-term health outcomes.

It might help them approve the drug permanently in the future, but, for now, that isn't the goal.

For retirees, that means this window could be short. Waiting too long to apply for coverage might limit how many months you can use the medication.

What comes after: the 2027 BALANCE model

In 2027, Medicare plans to shift into something more permanent called the BALANCE model. However, coverage may depend on the plan you choose. Not every Part D or Medicare Advantage plan is expected to participate.

That's an important difference from the drug just being "approved" across the board. Coverage may technically exist, but it might not exist for you, specifically.

Why your plan choice will matter more than usual

This is where you can start having some control over the process. During Open Enrollment, the details of your plan could directly impact whether you can access these medications.

If you're interested in these medications, you should check each plan's formulary to see if they're covered. Check for prior authorization requirements and whether step therapy rules apply.

This is one of those situations where reading the fine print is actually important, more so than just reading the headline. It's not just about whether Medicare covers something. It's about whether your specific plan does.

Retirement News: Almost 80% of Americans fear a retirement age increase — here’s the real reason why

The bigger picture for retirees

It's easy to look at this and think, "Finally, Medicare is covering weight loss drugs." The truth is a little more measured. Access is expanding, but slowly and not for everyone. There will be several hoops to jump through, and for many retirees, the process might be quite complicated.

Still, this is a meaningful shift from the last few years. Just a year ago, there was essentially no path to coverage for weight loss alone. Now, there's at least a starting point.

Bottom line

Medicare is starting to slowly move on GLP-1 coverage, but only in a limited way. In 2026, some retirees may start to gain access to drugs like Wegovy and Zepbound through a short-term program, though approval isn't guaranteed and depends on your doctor and health profile.

The bigger shift might come in 2027, when coverage may expand but will depend largely on the plan you choose. It's essential to check your plan options carefully if you're considering these medications.

It may also be worth talking to your doctor before Open Enrollment so you can understand what documentation or authorizations may be required. That way, you can compare plans with real information in hand and make the right moves instead of scrambling after you've already locked in coverage for the year.

More from FinanceBuzz: